A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

Completed · Phase 1/Phase 2

Conditions studied: Lupus Nephritis, Systemic Lupus Erythematosus

In brief

This was a Phase 1b/2, multi-center study in which patients received KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).

Key facts

Study ID
NCT03393013
Run by
Kezar Life Sciences, Inc.
People needed
69
Starts
2018-02-20
Expected to finish
2022-08-04
Last updated by the study team
2025-11-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.